ORUM Total Assets
ORUM total assets. Based on the latest financial reports, ORUM (475830) holds total assets worth ₩312.82 Billion KRW (≈ $211.99 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see ORUM market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of ORUM (2022–2025)
Total assets of ORUM from 2022 to 2025. This chart illustrates how ORUM's total assets have evolved over time, based on quarterly financial data. See ORUM (475830) stock price for real-time trading data and today's change.
ORUM - Asset Composition Analysis
ORUM Total Assets Breakdown (December 2025)
ORUM total assets breakdown as of December 2025. ORUM's total assets of ₩312.82 Billion consist of 79.4% current assets and 20.6% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 2.4% |
| Accounts Receivable | ₩558.17K | 0.0% |
| Inventory | ₩0.00 | 0.0% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩0.00 | 0.0% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2022–2025)
This chart illustrates how ORUM's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore ORUM working capital to net assets to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: ORUM's current assets represent 79.4% of total assets in 2025, an increase from 59.5% in 2022.
- Cash Position: Cash and equivalents constituted 2.4% of total assets in 2025, down from 53.0% in 2022.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2022.
- Asset Diversification: The largest asset category is accounts receivable at 0.0% of total assets.
ORUM Competitors by Total Assets
Key competitors of ORUM based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
ORUM - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.63 | 28.33 | 22.03 |
| Quick Ratio | 1.63 | 28.33 | 22.03 |
| Cash Ratio | 0.00 | 1.31 | 5.21 |
| Working Capital | ₩107.47 Billion | ₩155.02 Billion | ₩121.18 Billion |
ORUM - Advanced Valuation Insights
This section examines the relationship between ORUM's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 7.92 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 10.1% |
| Total Assets | ₩169.32 Billion |
| Market Capitalization | $216.70 Million USD |
Valuation Analysis
Below Book Valuation: The market values ORUM's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: ORUM's assets grew by 10.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for ORUM (2022–2025)
The table below shows the annual total assets of ORUM from 2022 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | ₩169.32 Billion ≈ $114.75 Million |
+10.07% |
| 2024-12-31 | ₩153.84 Billion ≈ $104.25 Million |
-4.91% |
| 2023-12-31 | ₩161.78 Billion ≈ $109.64 Million |
+660.16% |
| 2022-12-31 | ₩21.28 Billion ≈ $14.42 Million |
-- |
About ORUM
Orum Therapeutics, Inc., a biopharmaceutical company, engages in the research and development of pharmaceuticals for cancer and immune diseases in South Korea and the United States. The company develops ORM-6151, which is in Phase I clinical trial for the treatment of acute myeloid leukemia and myelodysplastic syndromes; ORM-1153, which is in pre-clinical trial for the treatment of acute myeloid … Read more